Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XKDCT293 in advanced breast cancer
NCT06724835Phase 1Recruiting
- Sponsor
- Shenzhen Celconta Life Science Co., Ltd.
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XKDCT-293 in breast cancer, sponsored by Shenzhen Celconta Life Science Co., Ltd. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Events at 1 year and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
XKDCT-293
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06724835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06724835.